CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 22 enrolled
Drug / intervention
Duodena-jejunal linerdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02183935
NCT02183935Phase 3Completed

Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner - a Study on Efficacy and Pathophysiologic Mechanisms

University Medical Centre Ljubljana·interventional·Posted Jul 8, 2014·Updated Jul 10, 2020

In Brief

A Phase 3 clinical trial evaluating Duodena-jejunal liner for Obesity and 2 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Obesity and its complications have a significant effect on morbidity and mortality in these subjects. Especially at risk are subjects with extremely increased BMI (above 99th percentile for age and gender in adolescents). In these subjects classical treatment with diet and cognitive therapy has a limited effect. Bariatric procedures, at the moment, are the only feasible therapeutic possibility. Bariatric procedures are based on several principles; restrictive, malabsorptive and combined. They can be surgical or endoscopic. The later are used in subjects that do not qualify for surgical procedures that decline them or are used before a planed definite bariatric procedure. Duodena-jejunal liner (DJL) is an endoscopic tool, that is efficiently and safely used to decrease body weight and ameliorated obesity complications, especially those associated with diabetic state. Aims of the study are: * To determine (short and long-term) efficacy of DJL in decreasing body weight in adolescents. * To determine (short and long-term) efficacy of DJL in ameliorating complications of morbid obesity - abnormal glucose metabolism, dislipidemia, altered adipokine secretion pattern, altered secretion pattern of gastrointestinal hormones in adolescents. * To visualize functional alternations in the selected central nervous system regions associated with appetite regulation upon insertion of DJL. * To evaluate psychological outcomes; change in emotional and behaviour problems, in body image, in eating disorder symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSlovenia
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 8, 2014
Enrollment StartJul 1, 2014
Primary CompletionDec 10, 2018
Study CompletionDec 20, 2018
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.0 years ago

Interventions

Duodena-jejunal linerdevice